UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 1, 2011
PEDIATRX INC.
(Exact name
of registrant as specified in its charter)
| Nevada | 000-52218 | 20-2590810 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
| incorporation) |
| 405 Trimmer Road, Suite 200, Califon, NJ | 07830 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (908) 975-0753
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events.
A copy of our press release dated June 1, 2011 is furnished herewith.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | PediatRx, Inc. Press Release dated June 1, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PEDIATRX INC.
| /s/ Cameron Durrant | |
| Cameron Durrant | |
| President, Chief Executive Officer and Director | |
| Date: June 1, 2011 |
80% of oncologists prefer medications with no patient out-of-pocket costs
GRANISOL’s co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients
CALIFON, NJ – June 1, 2011 – PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, recently polled a representative sample of approximately 70 US oncologists and other physician specialists and found that the majority (78%) viewed “no patient out-of-pocket costs” as a motivating factor for prescribing GRANISOL.
GRANISOL is the only FDA-approved oral solution of granisetron, a medication used to prevent nausea and vomiting in patients undergoing chemotherapy or radiotherapy for cancer. GRANISOL may be administered only once daily for one day (on the day of chemotherapy or radiotherapy), potentially offering more convenience to patients.*
80% of oncologists polled said that if the patient had no out-of-pocket expense, they would consider using GRANISOL oral solution instead of an injectable or a tablet formulation.
When prescribers were asked about GRANISOL, 61% of them said that they prefer GRANISOL’s dosing regimen over currently available anti-nausea treatment regimens.
A second poll asked these prescribers the percentage of patients they would anticipate using GRANISOL for, if the patients did not incur out-of-pocket expenses. Over 100 oncologists and other physician specialists responded, and 57% said they would prescribe GRANISOL for 20% or more of their patients for the prevention of nausea and vomiting associated with chemotherapy or radiotherapy for cancer.
PediatRx offers a co-pay assistance program that can help non-Medicaid or non-Medicare patients pay for GRANISOL. This program, “GRANI Cares,” covers the cost of the co-pay for the patient, has no income ceiling, and has no limit on the number of prescriptions that qualify.
The co-pay assistance program, in conjunction with the once-daily oral solution formulation has garnered positive response from the physicians who responded to this poll.
GRANISOL is indicated for the prevention of:
Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.
*For full prescribing information, visit: http://www.pediatrx.com/products/pdf/granisol_pi.pdf
Selected Safety Information
Polls were conducted using Sermo, the largest active social network of verified US physicians.
For the PediatRx co-pay program for GRANISOL, GRANI Cares, please visit: http://www.121hm.com/offers/granisol
For disclaimer information, visit: http://www.121hm.com/offers/granisol/tandc.html
For further information related to material contained in this release, please contact Holmes World Media Inc., +1 512 981 7369
About PediatRx, Inc.
PediatRx, Inc. (www.pediatrx.com) is a hospital specialty
pharmaceutical company which focuses on treatments for patients suffering from
serious conditions requiring hospitalization. PediatRx trades on the OTCBB under
the ticker symbol PEDX.
About Sermo
Sermo is the largest online
physician community, where over 120,000 physicians collaborate to improve
patient care. Sermo provides access to its community for clients that need fast,
actionable insights.
Further Information
PediatRx,
Inc.
Research & Business Development
Email: info@pediatrx.com
Shareholder Relations
+1 908 975 0753
Email: ir@pediatrx.com
Sermo Contact:
Jon Michaeli
Sermo, Inc.
P:
617-497-1110
E: jmichaeli@sermo.com